LOUISVILLE, Colo., June 8 /PRNewswire/ -- GlobeImmune, Inc. today announced the initiation of a randomized, placebo-controlled, multi-center Phase 2 clinical trial of GI-4000, GlobeImmune’s therapeutic vaccine for the treatment of patients with early-stage pancreas cancer. The primary goal of the study is to compare the recurrence-free survival at 15 months in patients treated with either GI-4000 or placebo, in combination with adjuvant gemcitabine after surgery. Pancreas cancer is an aggressive, deadly disease; median overall survival for patients eligible for this trial has been typically 13-20 months. GI-4000 is a Tarmogen(TM) (Targeted Molecular Immunogen), GlobeImmune’s proprietary yeast-based vaccine system that is designed to stimulate “killer” T cells in the immune system to find and destroy diseased cells.
